Electric field device tested for Hard-to-Treat brain tumor

NCT ID NCT01892397

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This pilot study tests an experimental device called Optune in people with recurrent atypical or anaplastic meningioma, a type of brain cancer that has come back after surgery or radiation. The device delivers electric fields to the tumor area to try to stop cancer cells from growing. The study aims to see if Optune can improve progression-free survival and overall survival, and whether it is safe and tolerable for these patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Optune (NovoTTF-100A) device
What this could lead to: If effective, Optune could offer a new treatment option for patients with recurrent meningioma that has not responded to surgery or radiation.
What could go wrong: This is a very small pilot study with only 6 participants, so results may not apply broadly. The device is experimental for this tumor type and may not slow tumor growth or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic meningioma brain cancer grade II meningioma meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN CANCER

Contacts and locations

Show contact details

Locations

Cedars-Sinai Medical Center

Los Angeles, California, United States
Columbia University

New York, New York, United States
Memorial Sloan Kettering Cancer Center

Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center at Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering West Harrison

Harrison, New York, 10604, United States
University of Cincinnati

Cincinnati, Ohio, United States
University of Colorado

Denver, Colorado, United States
University of Miami

Miami, Florida, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.